ProfileGDS5678 / 1430315_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 40% 39% 47% 38% 39% 40% 39% 39% 38% 40% 39% 39% 39% 39% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.963640
GSM967853U87-EV human glioblastoma xenograft - Control 22.893539
GSM967854U87-EV human glioblastoma xenograft - Control 33.0958347
GSM967855U87-EV human glioblastoma xenograft - Control 42.8229638
GSM967856U87-EV human glioblastoma xenograft - Control 52.8465439
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.0047240
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.9501239
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.8887639
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.8506538
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.8942740
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.8878239
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.8513839
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.8982639
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.8903139